GLP-1 use among young children with obesity in US remains rare but is rising rapidly. The number is 310 times higher in June 2026 than it was in 2019, when the drugs were initially prescribed. An estimated 20 percent of children in the US have obesity
Read Full Article
#PediatricObesity #GLP1 #ChildHealthScience
Read Full Article
#PediatricObesity #GLP1 #ChildHealthScience
EurekAlert!
GLP-1 use among young children with obesity in US remains rare but is rising rapidly
Although the number of US children under age 12 with obesity being prescribed the weight loss drugs Saxenda, Wegovy, and Zepbound remains low, the number is 310 times higher in June 2026 than it was in 2019, when the drugs were initially prescribed, a new…
🤬1